Novo Nordisk's new Wegovy GLP-1 pill is rapidly expanding the obesity treatment market by attracting patients who avoided injections due to fear of needles or high costs. Early users report varied experiences, with some seeing weight loss and appetite reduction, while others face side effects or limited results. The pill's lower price and oral form appeal to new patients rather than converting existing injection users. Competition from Eli Lilly's newly approved GLP-1 pill is expected, but Wegovy has had a strong launch with over 600,000 prescriptions in three months. Long-term effectiveness and patient adherence remain to be seen as Novo reports first-quarter sales including the pill in May.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
